3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
6
Lymphoma, Mantle-Cell
5
Waldenstrom Macroglobulinemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Burkitt Lymphoma
1
Interventions
tisagenlecleucel
8
Cyclophosphamide
7
fludarabine
5
blinatumomab
5
aflibercept
4
ibrutinib
2
epratuzumab
2
Vincristine
2
Radioimmunodetection
2
Methotrexate
2
MLN 8237
2
Inotuzumab Ozogamicin
2
Dexamethasone
2
tocilizumab
1
tafasitamab
1
siltuximab
1
sepantronium
1
ruxolitinib
1
relatlimab
1
pembrolizumab
1
pegaspargase
1
ontuxizumab
1
obinutuzumab
1
loncastuximab tesirine
1
forodesine
1
fludarabine phosphate
1
fiu protein, E coli
1
exatecan
1
brexucabtagene autoleucel
1
asparaginase erwinia chrysanthemi recombinant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Burkitt Lymphoma
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts